Raymond James upgraded HealthEquity (NASDAQ:HQY) from Outperform to Strong Buy, setting a new price target of $115, slightly below the previous $120, citing confidence in the company’s ability to ...

HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.

Raymond James upgraded HealthEquity (HQY) to Strong Buy from Outperform with a price target of $115, down from $120. The firm upgrade the ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...

Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (NasdaqGS:HQY) from Outperform ...

The healthcare finance company posted its final set of financials for its fiscal 2024. These fell short of expectations on several metrics. HealthEquity divulged its fourth-quarter and full-year ...

We recently published a list of Pulse of the Market: Wednesday’s 10 Worst Performers. In this article, we are going to take a look at where HealthEquity Inc. (NASDAQ:HQY) stands against other ...

We recently published a list of Pulse of the Market: Wednesday’s 10 Worst Performers. In this article, we are going to take a look at where HealthEquity Inc. (NASDAQ:HQY) stands against other ...

Shares of HealthEquity (NASDAQ:HQY) fell ~20% on Wednesday, marking its biggest one-day decline in more than three years, after the health savings account (HSA) administrator failed to meet Street ...

HealthEquity stock drops after mixed Q4 results despite 18.8% revenue growth. Click here to find out why HQY stock is a Hold.

Investing.com - Healthequity Inc (NASDAQ:HQY) shares tumbled 20% in early trading Wednesday after the health savings account provider reported fourth-quarter earnings that fell short of analyst ...